Cations affect [3H] mazindol and [3H] WIN 35,428 binding to the human dopamine transporter in a similar fashion

Journal of Neurochemistry

Volumn 69, Issue 3, 1997, Pages 1106-1118

  Wu, Qun ^a   Coffey, Lori L ^b   Reith, Maarten E A ^a,b,c  

^a ILLINOIS STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Cations; Dopamine transporter; Human; Mazindol binding; WIN 35,428 binding

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; MAZINDOL; (1R (EXO,EXO)) 3 (4 FLUOROPHENYL) 8 METHYL 8 AZABICYCLO(3.2.1)OCTANE 2 CARBOXYLIC ACID, METHYL ESTER; (1R-(EXO,EXO))-3-(4-FLUOROPHENYL)-8-METHYL-8- AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, METHYL ESTER; CARRIER PROTEIN; COCAINE; DIVALENT CATION; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; DRUG DERIVATIVE; LITHIUM; MAGNESIUM; MEMBRANE PROTEIN; MERCURY; MONOVALENT CATION; NERVE PROTEIN; POTASSIUM; SLC6A3 PROTEIN, HUMAN; SLC6A3 PROTEIN, RAT; SODIUM; TRITIUM; ZINC;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CATION TRANSPORT; CELL STIMULATION; DOPAMINE UPTAKE; DRUG RECEPTOR BINDING; GLIOMA CELL; HUMAN; HUMAN CELL; LIGAND BINDING; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; ANIMAL; CELL CULTURE; CELL MEMBRANE; CORPUS STRIATUM; DRUG EFFECT; GLIOMA; KINETICS; METABOLISM; PROTEIN BINDING; RAT;

ANIMALS; CARRIER PROTEINS; CATIONS, DIVALENT; CATIONS, MONOVALENT; CELL MEMBRANE; COCAINE; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; GLIOMA; HUMANS; KINETICS; LITHIUM; MAGNESIUM; MAZINDOL; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MERCURY; NERVE TISSUE PROTEINS; POTASSIUM; PROTEIN BINDING; RATS; SODIUM; TRITIUM; TUMOR CELLS, CULTURED; ZINC;

EID: 0030611085     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.69031106.x     Document Type: Article

References (57)

1. + dependence of the neuronal transport of dopamine. J. Neurochem. 59, 1795-1804.
2. Amejdki-Chab N., Costentin J., and Bonnet J.-J. (1992b) Kinetic analysis of the chloride dependence of the neuronal uptake of dopamine and effect of anions on the ability of substrates to compete with the binding of the dopamine uptake inhibitor GBR 12783. J. Neurochem. 58, 793-800.
3. 3H]GBR 12935 binding in vitro to rat striatal membranes: labeling of the dopamine uptake complex. J. Neurochem. 48, 1887-1896.
4. Berger P., Gawin F., and Kosten T. R. (1989) Treatment of cocaine abuse with mazindol [letter] [see comments]. Lancet i, 283.
5. 3H]GBR 12783 to a site associated with the dopamine uptake carrier. J. Neurochem. 50, 759-765.
6. 3H]mazindol. J. Pharmacol. Exp. Ther. 253, 1206-1214.
7. 2+. Eur. J. Pharmacol. 266, 87-97.
8. Calligaro D. O. and Eldefrawi M. E. (1987) High affinity stereospecific binding of [3H] cocaine in striatum and its relationship to the dopamine transporter. Membr. Biochem. 7, 87-106.
9. 125I]iodophenyl)tropane-2β-carboxylic acid isopropyl ester to the dopamine transporter. J. Neurochem. 68, 1968-1981.
10. 3H]WIN 35,428 binding to the dopamine uptake carrier. I. Effect of tonicity and buffer composition. J. Neurosci. Methods 51, 23-30.
11. DeLean A., Munson P. J., and Rodbard D. (1978) Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235, E97-E102.
12. Diliberto P. A., Jeffs R. A., and Cubeddu L. X. (1989) Effects of low extracellular chloride on dopamine release and the dopamine transporter. J. Pharmacol. Exp. Ther. 248, 644-653.
13. Eide D., Broderius M., Fett J., and Guerinot M. L. (1996) A novel iron-regulated metal transporter from plants identified by functional expression in yeast. Proc. Natl. Acad. Sci. USA 93, 5624-5628.
14. Eshleman A. J., Calligaro D. O., and Eldefrawi M. E. (1993) Allosteric regulation by sodium of the binding of [3H] cocaine and [3H]GBR 12935 to rat and bovine striata. Membr. Biochem. 10, 129-144.
15. Eshleman A. J., Henningsen R. A., Neve K. A., and Janowsky A. (1994) Release of dopamine via the human transporter. Mol. Pharmacol. 45, 312-316.
16. Eshleman A. J., Neve R. L., Janowsky A., and Neve K. A. (1995) Characterization of a recombinant human dopamine transporter in multiple cell lines. J. Pharmacol. Exp. Ther. 274, 276-283.
17. Garris P. A., Ciolkowski E. L., Pastore P., and Wightman R. M. (1994) Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J. Neurosci. 14, 6084-6093.
18. Giros B., Jaber M., Jones S. R., Wightman R. M., and Caron M. G. (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612.
19. Gu H., Wall S. C., and Rudnick G. (1994) Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J. Biol. Chem. 269, 7124-7130.
20. 3H]GBR 12783 binding to the dopamine neuronal carrier. Eur. J. Pharmacol. 301, 195-202.
21. Heron D. S., Shinitzky M., Hershkowitz M., and Samuel D. (1980) Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. Proc. Natl. Acad. Sci. USA 77, 7463-7467.
22. 3H]-Mazindol binding associated with neuronal dopamine and norepinephrine uptake sites. Mol. Pharmacol. 26, 35-44.
23. Kennedy L. T. and Hanbauer I. (1983) Sodium-sensitive cocaine binding to rat striatal membrane: possible relationship to dopamine uptake sites. J. Neurochem. 41, 172-178.
24. Kilty J. E., Lorang D., and Amara S. G. (1991) Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 254, 578-579.
25. + transport. Synapse 15, 58-62.
26. 125I]iodophenyl)tropane-2β-carboxylate in vitro binding to dopamine and serotonin transporters under "physiological" conditions. J. Neurochem. 62, 978-986.
27. 3H] Cocaine binding sites in caudateputamen. J. Pharmacol. Exp. Ther. 251, 131-141.
28. 3H]2β-carbomethoxy-3β-(4-fluorophenyl)tropane. Mol. Pharmacol. 36, 518-524.
29. 3H]BTCP, a phencyclidine derivative) binding to the dopamine uptake complex. Neuropharmacology 30, 591-598.
30. McElvain J. S. and Schenk J. O. (1992) A multisubstrate mechanism of striatal dopamine uptake and its inhibition by cocaine. Biochem. Pharmacol. 43, 2189-2199.
31. Meiergerd S. M. and Schenk J. O. (1994) Kinetic evaluation of the commonality between the site (s) of action of cocaine and some other structurally similar and dissimilar inhibitors of the striatal transporter for dopamine. J. Neurochem. 63, 1683-1692.
32. Munson P. J. and Rodbard D. (1980) Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107, 220-239.
33. Palmiter R. D. and Findley S.D. (1995) Cloning and functional characterization of a mammalian zinc transporter that confers resistance to zinc. EMBO J. 14, 639-649.
34. Povlock S. and Amara S. G. (1997) The structure and function of norepinephrine, dopamine, and serotonin transporters, in Neurotransmitter Transporters: Structure, Function, and Regulation (Reith M. E. A., ed), pp. 1-28. Humana Press, Totowa, New Jersey.
35. Preston K. L., Sullivan J. T., Berger P., and Bigelow G. E. (1993) Effects of cocaine alone and in combination with mazindol in human cocaine abusers. J. Pharmacol. Exp. Ther. 267, 296-307.
36. 3H] cocaine binding sites. Naunyn Schmiedebergs Arch. Pharmacol. 351, 136-145.
37. 3H]tropane to the dopamine uptake carrier. J. Neurochem. 61, 167-177.
38. Reith M. E. A. and Selmeci G. (1992) Cocaine binding sites in mouse striatum, dopamine autoreceptors, and cocaine-induced locomotion. Pharmacol. Biochem. Behav. 41, 227-230.
39. Reith M. E. A., de Costa B., Rice K. C., and Jacobson A. E. (1992) Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. Eur. J. Pharmacol. 227, 417-425.
40. 3H]WIN 35,428) binding. Biochem. Pharmacol. 52, 1435-1446.
41. Reith M. E. A., Xu C., Zhang L., and Coffey L. L. (1996b) Translocation of dopamine and binding of WIN 35,428 measured under identical conditions in cells expressing the cloned human dopamine transporter. Naunyn Schmiedebergs Arch. Pharmacol. 354, 295-304.
42. 3H]-cocaine analog binding - a potential screening device for cocaine antagonists, in Neurotransmitter Transporters (Amara S., ed), Academic Press, San Diego (in press).
43. Reith M. E. A., Xu C., and Chen N.-H. ( 1997b) Pharmacology and regulation of the neuronal dopamine transporter. Eur. J. Pharmacol. 324, 1-10.
44. Richfield E. K. (1993) Zinc modulation of drug binding, cocaine affinity states, and dopamine uptake on the dopamine uptake complex. Mol. Pharmacol. 43, 100-108.
45. Ritz M. C., Lamb R. J., Goldberg S. R., and Kuhar M. J. (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237, 1219-1223.
46. Rosenzweig-Lipson S., Bergman J., Spealman R. D., and Madras B. K. (1992) Stereoselective behavioral effects of Lu 19-005 in monkeys: relation to binding at cocaine recognition sites. Psychopharmacology (Berl.) 107, 186-194.
47. 3H]methylphenidate to the dopamine transporter. Synapse 16, 188-194.
48. 3H]Threo-(±)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J. Neurochem. 45, 1062-1070.
49. Shank R. P., Schneider C. R., and Tighe J. J. (1987) Ion dependence of neurotransmitter uptake: inhibitory effects of ion substitutes. J. Neurochem. 49, 381-388.
50. Shimada S., Kitayama S., Lin C. L., Patel A., Nanthakumar E., Gregor P., Kuhar M., and Uhl G. (1991) Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA [published erratum appears in Science 255, 1195 (1992)]. Science 254, 576-578.
51. Supek F., Supekova L., Nelson H., and Nelson N. (1996) A yeast manganese transporter related to the macrophage protein involved in conferring resistance to mycobacteria. Proc. Natl. Acad. Sci. USA 93, 5105-5110.
52. Vaughan R. A. (1995) Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping. Mol. Pharmacol. 47, 956-964.
53. Vaughan R. A. and Kuhar M. J. (1996) Dopamine transporter ligand binding domains. Structural and functional properties revealed by limited proteolysis. J. Biol. Chem. 271, 21672-21680.
54. Xu C. and Reith M. E. A. (1997) WIN 35,428 and mazindol are mutually exclusive in binding to the cloned human dopamine transporter. J. Pharmacol. Exp. Ther. 278, 1340-1348.
55. Xu C., Coffey L. L., and Reith M. E. A. (1995) Translocation of dopamine and binding of 2β-carbomethoxy-3β-(4-fluorophenyl)tropane (WIN 35,428) measured under identical conditions in rat striatal synaptosomal preparations. Inhibition by various blockers. Biochem. Pharmacol. 49, 339-350.
56. Zhao H. and Eide D. (1996) The yeast ZRTI gene encodes the zinc transporter protein of a high-affinity uptake system induced by zinc limitation. Proc. Natl. Acad. Sci. USA 93, 2454-2458.
57. Zimanyi I., Lajtha A., and Reith M. E. A. (1989) Comparison of characteristics of dopamine uptake and mazindol binding in mouse striatum. Naunyn Schmiedebergs Arch. Pharmacol. 340, 626-632.